Biological assessment and human absorbed dose estimation of [۱۱۱In]In-DTPA-antiMUC۱ as a radioimmunoconjugate for breast cancer imaging

Introduction: The aim of this study was to evaluate the human organ absorbed dose of [۱۱۱In]In-DTPA-antiMUC۱, as a newly developed radioimmunoconjugate. Methods: [۱۱۱In]In-DTPA-antiMUC۱ was prepared at optimized conditions while the radiochemical purity of the tracer was investigated using ITLC method. Biodistribution of the radiolabeled complex was assessed in tumor bearing BALB/c mice and the human absorbed dose of the radiotracer was estimated based on the gathered data in animals according to the standard methods. Results: The highest absorbed dose is observed in the spleen and the liver with ۰.۱۱۲ and ۰.۰۸۷ mGy/MBq, respectively. In addition, the estimated human equivalent and effective absorbed dose were ۰.۰۰۸ mGy/MBq and ۰.۰۴۱ mSv/MBq, respectively. Conclusion: [۱۱۱In]In-DTPA-antiMUC۱ radioimmunoconjugate can be considered as an effective and safe radiolabeled compound for MUC۱ positive breast cancer SPECT imaging.

Keywords:

Indium-۱۱۱ , antiMUC۱ , Breast cancer , Absorbed dose , RADAR